EVORA Biosciences is developing a proprietary peptide platform as a therapeutic alternative to corticosteroids — advanced in parallel across dermatology and ophthalmology.
Corticosteroids remain the default treatment for inflammatory disease — inexpensive, fast-acting, and everywhere. But long-term use comes at a cost: side effects that accumulate, efficacy that fades, and patients who become resistant or dependent on ever-increasing doses.
For the millions of people managing chronic inflammatory conditions of the skin and the eye, that trade-off is a daily reality. Medicine still lacks a broadly available alternative that spares patients from it.
EVORA is developing steroid-sparing therapeutics built on a proprietary peptide platform, designed to work alongside or in place of corticosteroids — reducing dependence on them without giving up efficacy. A single scientific foundation is advanced in parallel toward two therapeutic areas, keeping development capital-efficient while EVORA retains full ownership of where the platform goes next.
At the molecular level, EVORA's peptides act through an immunomodulatory mechanism, engaging both the NF-κB and IRF-1 signalling pathways — two of the principal routes through which inflammatory and immune responses are triggered and sustained.
Precise biology and a well-understood safety profile, rather than a broad-acting small molecule.
Inflammatory mechanisms are highly redundant — addressing multiple pathways is essential in a steroid-sparing approach.
The platform belongs to EVORA outright, with composition-of-matter protection across multiple therapeutic areas.
Whether you're an investor, a potential partner, or interested in joining our work, we'd like to hear from you.
